1 Title

2 A systematic analysis of splicing variants identifies new diagnoses in the 100,000 Genomes Project.

3 Authors

Alexander J.M. Blakes^{1,2}, Htoo Wai¹, Ian Davies³, Hassan E. Moledian¹, April Ruiz⁴, Tessy Thomas⁴,
David Bunyan^{5,6}, N Simon Thomas^{5,6}, Christine P. Burren^{7,8}, Lynn Greenhalgh⁹, Melissa Lees¹⁰, Amanda
Pichini^{11,12}, Sarah F. Smithson¹¹, Ana Lisa Taylor Tavares^{12,13}, Peter O'Donovan¹², Andrew G.L.
Douglas^{14,1}, Genomics England Research Consortium, Splicing and Disease Working Group, Nicola
Whiffin¹⁵, Diana Baralle^{1,4,*}, Jenny Lord^{1,*,**}

9 * Joint senior author

10 ** Corresponding author: jenny.lord@soton.ac.uk

11 Affiliations

12 1. Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK; 2. National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK; 3. 13 14 Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; 4. Wessex 15 Clinical Genetics Service, Princess Anne Hospital, Southampton, UK; 5. Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, UK; 6. School of Medicine, University of 16 Southampton, Southampton, UK; 7. Department of Paediatric Endocrinology and Diabetes, University 17 18 Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK; 8. Bristol Medical School, Dept of 19 Translational Health Sciences, University of Bristol, Bristol, UK; 9. Liverpool Centre for Genomic 20 Medicine, Crown Street, Liverpool, UK; 10. North East Thames Regional Genomics Service, Great 21 Ormond Street Hospital, London, UK; 11. Department of Clinical Genetics, University Hospitals Bristol 22 avorté/viese programadatioew Tresser, conisto de but pala com annique de region de Deaverone Hollis Charge en house a seu avec,

London, UK; 13. Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical
 Campus, Hills Road, Cambridge, UK; 14. Oxford Centre for Genomic Medicine, Oxford University
 Hospitals NHS Foundation Trust, Oxford, UK; 15. Wellcome Centre for Human Genetics, University of
 Oxford, Oxford, UK

27 Abstract

28 Genomic variants which disrupt splicing are a major cause of rare genetic disease. However, variants 29 which lie outside of the canonical splice sites are difficult to interpret clinically. Here, we examine the 30 landscape of splicing variants in whole-genome sequencing data from 38,688 individuals in the 31 100,000 Genomes Project, and assess the contribution of non-canonical splicing variants to rare 32 genetic diseases. We show that splicing branchpoints are highly constrained by purifying selection, 33 and harbour damaging non-coding variants which are amenable to systematic analysis in sequencing data. From 258 de novo splicing variants in known rare disease genes, we identify 35 new likely 34 35 diagnoses in probands with an unsolved rare disease. We use phenotype matching and RNA studies 36 to confirm a new diagnosis for six individuals to date. In summary, we demonstrate the clinical value 37 of examining non-canonical splicing variants in participants with unsolved rare diseases.

38 Introduction

Improved diagnosis of rare genetic diseases remains a significant clinical and research challenge¹.
Diagnostic yields in individuals with rare diseases remain below 50%, despite extensive investigations
including whole-genome sequencing². The accurate interpretation of genomic variants in existing
sequencing data presents an important opportunity to narrow the diagnostic gap³.

Splicing is the process by which introns are removed from a pre-mRNA primary transcript. Almost all
human protein coding genes are spliced, and disruption of splicing is a major cause of rare genetic
diseases⁴. The improved interpretation of splicing variants is therefore a major opportunity to improve
clinical outcomes for individuals with undiagnosed rare disease⁵.

Already, "canonical splice site" (CSS) variants within 2bp of an exon-intron junction are widely annotated as "loss of function" (LoF) variants, and are known to be strong diagnostic candidates in "loss-of function" disorders⁶. The contribution of non-canonical splicing variants to rare disease is also becoming increasingly recognised⁷. Up to 27% of pathogenic *de novo* splicing variants in exomesequencing data are found in non-canonical positions⁸. Several studies^{7–9} have developed the concept of a "near-splice" region, usually tens of base pairs around an exon-intron junction, which contains many conserved splicing motifs.

However, near-splice variants are under-reported in clinical databases⁸, and no standards exist for their interpretation. Furthermore, variants distal to the near-splice region, including branchpoint variants and deep intronic variants, can also disrupt splicing, and their overall contribution to rare disease is unknown. Individual instances of pathogenic branchpoint variants have been previously described^{10,11}, but they have not been systematically characterised in a large rare disease cohort.

59 Recently, large population genomic datasets have provided the statistical power necessary to measure 60 constraints on genetic variation within human populations. One powerful metric which uses this 61 approach is the mutability-adjusted proportion of singletons (MAPS)¹², which identifies classes of

variation which are subject to purifying selection, and are therefore likely to be deleterious. MAPS has
 previously been calculated in many contexts, including for near-splice positions in the Exome
 Aggregation Consortium (ExAC)⁸, and for upstream start-codon-creating variants in Genome
 Aggregation Database (gnomAD)¹³.

Recent advances in computation and artificial intelligence have led to the development of numerous *in silico* predictors for the prioritization of splicing variants¹⁴. For example, SpliceAI is a machine learning tool which robustly predicts splice sites and splice-disrupting variants¹⁵, and out-performs other algorithms in predicting splicing consequences from sequence data¹⁶. However, in clinical variant interpretation, well-validated functional assays have greater weight than *in silico* predictions of variant effect⁶, and functional validation of most splicing variants is still required to confirm a molecular diagnosis.

73 Here, we perform a systematic analysis of splicing variants in whole-genome sequencing data from 38,688 individuals in the Rare Disease arm of the 100,000 Genomes Project (100KGP)¹⁷. We evaluate 74 75 the contribution of canonical, near-splice, and splicing branchpoint variants to rare genetic diseases 76 in this cohort. We show that splicing branchpoints harbour deleterious non-coding variants which are 77 amenable to systematic analysis in WGS data. We used a gene-agnostic approach to prioritise 258 de novo splicing variants in families affected by a rare genetic disorder. Of these, at least 84 were already 78 79 considered to be diagnostic, and we identified an additional 35 variants which are likely to be 80 diagnostic given the available molecular, phenotypic, and *in silico* data. We confirmed a new molecular diagnosis for six participants, including four out of five participants for whom RNA studies were 81 82 performed. Ultimately, we demonstrate the clinical and diagnostic value of examining both canonical and non-canonical splicing variants in unsolved rare diseases. 83

4

84 Subjects and Methods

85 Cohort, sequencing, and tiering

86 This analysis was performed on whole-genome sequencing data from 38,688 participants in the Rare Disease arm of the 100,000 Genomes Project¹⁸. These comprised 26,660 unaffected parents of rare 87 disease probands, and 12,028 participants (offspring) for whom trio WGS data was available. Only 88 89 participants for whom WGS data was aligned to GRCh38 were included in this study. Parents affected 90 by a rare genetic disease were excluded from the analysis of variant constraint (see below). Otherwise, 91 participants were not selected or stratified by any other criterion. The sequencing and bioinformatic 92 pipelines, as well as the "tiering" framework for variant prioritisation, have been previously 93 described¹⁷. Briefly, variants meeting filtering criteria and falling within applied virtual gene panels 94 were annotated as tier 1 (loss of function or *de novo* protein-altering variants), tier 2 (other variant 95 types eg missense, with correct mode of inheritance), or tier 3 (all other filtered variants). For example, 96 CSS variants in an appropriate gene panel are annotated as tier 1.

97 Defining CDS exons and near-splice positions

98 We identified coding sequences in high-confidence protein-coding transcripts from GENCODE v29¹⁹ 99 (GRCh38) using the following filtering criteria: feature type = "CDS", gene_type = "protein_coding", 100 transcript_type = "protein_coding", level != "level 3", and tag = "CCDS", "appris_principal_1", 101 "appris_candidate_longest", "appris_candidate", or "exp_conf". 401,314 CDS features (207,548 102 unique) met these criteria. Only autosomal CDS were included in the subsequent analyses. UTR and 103 other non-coding exons were not included in this analysis.

For each CDS feature, we annotated individual genomic positions with their positions relative to a splice donor or acceptor site, excluding any sites with conflicting annotations. We defined the nearsplice region around the acceptor site as 25bp of intronic sequence (acceptor -25 to acceptor -1), and 11bp of exonic sequence (acceptor 0 to acceptor +10). Around the donor site, we included 11bp of

108 exonic sequence (donor -10 to donor 0) and 10 bp of intronic sequence (donor +1 to donor +10).

109 9,588,491 distinct near-splice positions were identified.

110 phyloP

- 111 We annotated each near-splice position with phyloP scores from multiple alignments of 99 vertebrate
- species to the human genome (phyloP 100-way)²⁰ with pyBigWig, an open-source Python package²¹,
- using BigWig files downloaded from the UCSC genome browser (hg38)^{22,23}.

114 SpliceAl

- 115 For every possible near-splice SNV in our positions of interest (i.e. all three possible single base
- 116 changes at each of the 9,588,491 positions), we annotated the predicted effect on splicing with
- 117 SpliceAl¹⁵. We annotated variants with pre-computed genome-wide SpliceAl v1.3 scores (available via
- 118 <u>https://github.com/Illumina/SpliceAI</u>) using BCFtools v1.9²⁴. A SpliceAI annotation was available for
- 119 28,265,193 variants (98.2% of 28,765,473 possible variants).
- Aggregate SpliceAI scores for each near-splice position were calculated as the mean probability that any variant at this position disrupts splicing. The probability that a given variant disrupts splicing was calculated as the probability (P) of any one of the SpliceAI-predicted splicing events occurring, (i.e. 1 probability of *no* events occurring). The predicted splicing events are acceptor gain (AG), acceptor loss (AL), donor gain (DG), or donor loss (DL), giving:
- 125 P = 1 ((1 (AG)) * (1 (AL)) * (1 (DG)) * (1 (DL))

126 Mutability-adjusted proportion of singletons

127 In addition to the near-splice SNVs identified above, we also determined the set of all possible coding 128 SNVs in our exons of interest. These were annotated with the reference base for each position 129 (GRCh38, GenBank assembly accession GCA_000001405.15) and its immediate sequence context (1bp 130 either side) with bedtools version 2.27.1²⁵.

131 We annotated every possible coding SNV within our exons of interest with the Variant Effect Predictor (VEP) version 99^{26} . For each variant, only the consequence in one transcript (typically the canonical 132 133 transcript, as determined by VEP's "-pick" flag), was used. Only synonymous, missense, and nonsense variants were included in the subsequent analysis. Synonymous variants within a near-splice region 134 135 were classed as near-splice variants for the MAPS calculation and were excluded from the synonymous 136 variant set. Missense variants within a near-splice region were excluded from the analysis altogether. Nonsense variants within a near-splice region were classed as nonsense variants and excluded from 137 138 the near-splice variant set.

We interrogated whole genome sequencing data from 26,660 unaffected parents in the Genomics England (GEL) Rare Disease cohort for SNVs overlapping the near-splice and coding positions defined above using BCFtools v1.9²⁴. Only variants passing all filters (see https://researchhelp.genomicsengland.co.uk/display/GERE/aggV2+Details) within the GEL aggregated multi-sample VCF were included. We identified 915,024 synonymous, 1,965,441 missense, 53,825 nonsense, and 672,528 near-splice variants, and calculated allele counts across the 26,660 unaffected parents for each variant.

We calculated MAPS with custom Python scripts, adapting code written in R by Patrick J. Short²⁷ (<u>https://github.com/pjshort/dddMAPS</u>). We used the mutation rate of a given trinucleotide context calculated by Samocha et al²⁸. The proportion of singletons for each position was adjusted for the mutability of the immediate sequence context using a linear model trained on synonymous variants within the same exons.

151 Branchpoints

Splicing branchpoint positions were identified by LaBranchoR, a machine-learning tool trained on experimentally-validated branchpoints, which accurately identifies at least one branchpoint for the majority of introns genome-wide²⁹. Pre-computed LaBranchoR scores are publicly available for every

position 1-70bp upstream of a splice acceptor (GENCODE v19, hg19)²⁹. For each intron, the highest
 scoring position was annotated as the branchpoint (BP), totalling 195,863 putative branchpoints.

We converted each branchpoint to hg38 coordinates using the UCSC Liftover tool³⁰. We annotated five positions upstream (-5 to -1) and five positions downstream (+1 to +5) of each branchpoint, as well as every possible SNV at each of these positions using custom Python scripts. phyloP scores for each position, and SpliceAI scores for each variant, were determined as above. We calculated the MAPS statistic for these branchpoint positions in the same cohort of participants as described above. Comparison of MAPS scores in branchpoint positions was made to the same set of coding variants as described above.

164 Statistics

The null hypotheses that near-splice and branchpoint MAPS scores did not significantly differ from 165 166 synonymous variants were tested with two-sided Chi squared tests of the observed vs the expected 167 number of singletons in each variant class. In order that the synonymous MAPS did not equal zero, all 168 MAPS scores were first corrected by addition of the synonymous unadjusted proportion of singletons. 169 For each variant class the "observed" proportion of singletons was taken as the number of alleles 170 multiplied by the corrected MAPS score for that variant class. The "expected" number of singletons 171 was taken as the number of alleles multiplied by the corrected MAPS score for synonymous variants. Multiple testing was accounted for by Bonferroni correction: 79 tests at alpha = 0.05 gave a 172 173 significance threshold of $<6.3 \times 10^{-4}$.

174 De novo variants

De novo mutations (DNMs) overlapping near-splice positions were identified from a set of 1,004,599 high confidence *de novo* calls in 13,949 trios from 12,609 rare disease families. The annotation pipeline used to identify these variants is publicly available³¹. Briefly, a multisample VCF for each trio was annotated for putative DNMs using custom scripts. Putative DNMs were then filtered by a series of

"Global", "Base", and "Stringent" filters (see reference³¹). Unless otherwise stated, our analyses were
 performed on DNMs aligned to GRCh38 (870,559 DNMs in 12,028 trios).

181 At the outset of this project this dataset was not available. Preliminary work to identify candidate 182 diagnostic de novo variants was undertaken in a smaller set of 402,464 variants identified through a 183 custom filtering strategy by Patrick J. Short (Wellcome Sanger Institute, personal correspondence). 184 These variants were identified by applying post-processing filters to DNMs in 4,967 trios identified by 185 the GEL Platypus variant caller and aligned to GRCh38. They were filtered according to the following 186 criteria: genotype heterozygous in offspring and homozygous reference in both parents, no more than 187 one alternate allele read in either parent, variant allele frequency in the offspring between 0.3 and 0.7, greater than 20 sequencing reads in the offspring and both parents, fewer than 98 sequencing 188 189 reads in the offspring, no overlap with locus control regions, no overlap with hg38 "patch regions", no 190 other DNM within 20bp in the same individual. Some candidate variants identified in this preliminary 191 dataset are not present in the larger *de novo* set, owing to differences in the filtering pipeline. Unless 192 explicitly stated, the data presented here are from the larger DNM set, above.

193 Candidate diagnostic variants

194 To identify candidate diagnostic near-splice and branchpoint variants, we annotated all GRCh38 195 autosomal de novo SNVs passing the "stringent" filters (above) with VEP (version 99). For each variant, 196 only the consequence in one transcript per gene (determined by VEP's "--per gene" flag) was 197 considered. We annotated these variants with SpliceAI as described above. We filtered for variants 198 overlapping our branchpoint or near-splice positions of interest, finding 3,672 such variants. Where a 199 variant had both a branchpoint and a near-splice annotation, only the near-splice annotation was kept. 200 We then filtered for variants overlapping any known monoallelic rare disease gene with a loss of function mechanism using the G2P DD, G2P Eye, and G2P Skin gene lists³² (accessed 27/10/2021, 201 202 confirmed and probable genes only). In total we identified 258 candidate splicing DNMs (238 near-203 splice, 20 branchpoint) in 255 participants, across 137 genes.

204 To identify new diagnoses in the cohort, we annotated these variants with tiering data, phenotype data, and participant outcome data from the GEL bioinformatics pipeline³³. For each participant and 205 206 DNM, we manually reviewed the similarity between the HPO terms recorded at recruitment and the 207 phenotype expected for a loss-of-function variant in that gene. Excluding any participants whose case 208 was already solved through 100KGP, we identified 35 new likely diagnostic variants with at least a 209 plausible phenotype match. In each instance, we placed a clinical collaboration request with Genomics 210 England to recruit the participant to the Splicing and Disease Study for functional characterisation of 211 the variant.

Genomics England does not allow re-identification of participants outside of a secure research environment. In order to protect participant identities, the HPO terms given here are "abstracted" by moving up one level in the HPO hierarchy. For example "Tetralogy of Fallot" becomes "Conotruncal defect".

216 Functional validation

Samples from five participants underwent functional characterisation through the Splicing and Disease study at The University of Southampton. Blood was collected in PAXgene Blood RNA tubes, with the PAXgene Blood RNA kit (PreAnalytix, Switzerland) used to extract RNA. Random hexamer primers were used to synthesise complementary DNA (cDNA) by reverse transcription using the High-Capacity cDNA Reverse Transcription kit (ThermoFisher Scientific).

Reverse transcription polymerase chain reaction (RT-PCR) was used to test for splicing alterations.
Primers were designed for each variant to include at least two exons up- and downstream of the target
(primer sequences available upon request). Agarose gel electrophoresis was used to assess participant
vs control PCR products, and purified PCR products were analysed by Sanger sequencing.

226 Ethics

The 100,000 Genomes Project Protocol has ethical approval from the HRA Committee East of England
 Cambridge South (REC Ref 14/EE/1112). This study was registered with Genomics England under

229	Research Registry Projects 143, 165, and 166. The Splicing and Disease study has ethical approval from
230	the Health Research Authority (IRAS Project ID 49685, REC 11/SC/0269) and The University of
231	Southampton (ERGO ID 23056), with informed consent given for splicing studies in a research context.
232	Code
233	All analyses were performed within a protected research environment which is available to registered
234	users (see https://www.genomicsengland.co.uk/about-gecip/for-gecip-members/data-and-data-
235	access/). Clinical data and tiering data were accessed through the LabKey application within this
236	research environment. The analyses were performed using Python 3.7.6 and Pandas 1.2.1. Figures

- $237 \qquad \text{were generated in } R \quad 3.5.2 \quad \text{using } RStudio \quad 1.1.463. \quad \text{All code is available online at}$

238 <u>https://github.com/alexblakes/100KGP_splicing</u>.

239 Results

240 Signals of constraint at near-splice positions are replicated in a large healthy

241 cohort

To estimate the deleteriousness of variation in near-splice positions, we calculated aggregate measures of evolutionary conservation, selective constraint, and pathogenicity prediction for nucleotides within near-splice regions genome-wide.

Evolutionary conservation was measured by base-wise phyloP score. The CSSs are very highly conserved (mean phyloP = 6.34) (Figure 1). Other intronic splicing positions with high phyloP scores include the D+5 (3.44), D+4 (2.39), D+3 (1.97), A-3 (1.70), and D+6 (1.29) sites. Notably, the A-4 position is very weakly conserved (0.076). Coding positions are generally more highly conserved than intronic sequences. The redundancy of third codon positions and bias for in-phase exons³⁴ is reflected in lower phyloP scores at every third position, except for the donor 0 position (mean phyloP = 5.01), which is more highly conserved than any other coding position.

252 To measure selective constraint at near-splice positions, we calculated the degree of purifying selection acting at near-splice positions using MAPS¹². MAPS was calculated across near splice 253 254 positions genome-wide, using every observed synonymous, missense, nonsense, and near-splice SNV 255 in 207,548 distinct CDS exons for 26,660 unaffected parents in the 100KGP Rare Disease cohort. The 256 most significant signals of purifying selection are at the CSS, with MAPS scores of 0.089-0.146 257 $(p<1.2x10^{-43})$, approaching those of nonsense variants (0.16) (Figure 1). The non-canonical positions 258 with a MAPS score significantly above the synonymous baseline after Bonferroni correction include 259 the D-2, D0, D+3, D+4, D+5, D+6, A-3 and A+1 positions ($p<6.3x10^{-4}$). The MAPS scores at D0 and D+5 260 variants (MAPS = 0.057 and 0.067 respectively) are comparable to that at missense variants (0.052). 261 These results are highly concordant with previous near-splice MAPS calculations in the DDD and ExAC 262 datasets⁸.

A subset of splicing branchpoints are highly constrained

- Having replicated earlier findings⁸ in our cohort, we expanded our analysis to examine splicing
 branchpoints, which have not been previously characterised using MAPS.
- 266 We repeated our analysis of conservation, constraint, and SpliceAI predicted pathogenicity using a set
- 267 of 195,863 putative branchpoints predicted by LaBranchoR²⁹, a deep-learning tool trained on
- 268 experimentally-validated branchpoints.
- 269 Annotating each position with base-wise phyloP scores, we found modest conservation of BPO (0.62)
- and BP-2 (0.87), consistent with previous results²⁹ (Figure 1).

Next, we calculated the MAPS statistic for these branchpoint positions in the same cohort described above. When all putative branchpoints were considered, only the BP-2 position has a significantly higher MAPS score than the synonymous baseline (MAPS = 0.017, p=1.3 x 10⁻⁴) (Figure 1). However, when only the most confident branchpoints are considered (LaBranchoR score >0.85, n=57,342), the BPO (MAPS = 0.044, p=7.6x10⁻⁹) and BP-3 (0.024, p = 3.7×10^{-4}) are also significantly constrained. These data suggest that LaBranchoR-predicted branchpoints are functionally important, and that variants near branchpoints may be a significant cause of rare disease.

Next, we calculated SpliceAI scores for every possible SNV around each branchpoint. Again, variants
at BPO (0.15) and BP-2 (0.14) are nominally more likely to disrupt splicing than synonymous coding
variants (Figure 1). This trend is more pronounced when only the most confident branchpoints
(LaBranchoR score >0.85, n = 57,342) are considered (mean SpliceAI BPO = 0.22, BP-2 = 0.19).

282 New diagnostic candidates among near-splice *de novo* mutations

Having described three orthogonal metrics which independently suggest that certain near-splice and
branchpoint variants may be deleterious, we sought to identify new candidate diagnostic variants at
these positions.

We interrogated a set of 870,559 DNMs in 12,028 trios for potentially diagnostic splicing variants. We identified 258 *de novo* SNVs overlapping near-splice or branchpoint regions of known monoallelic "loss of function" rare disease genes in 255 individuals (Supplementary Table 1). Of these, 238 were in nearsplice positions, and 20 were within 5bp of a putative branchpoint. (12 variants had both a splice acceptor and a branchpoint annotation; in these cases only the splice acceptor annotation (e.g. A- 25) was kept).

Reviewing tiering data from the 100KGP bioinformatics pipeline, we found that of these 258 variants, 83 (32%) were "Tier 1", 46 (18%) were "Tier 3", and 129 (50%) were not tiered (Supplementary Figure 1). Of 59 CSS variants, 36 (61%) were "Tier 1", nine (15%) were "Tier 3", and 14 (24%) were not tiered. Of ten donor +5 variants, four were "Tier 1", two were "Tier 3" and four were not tiered (Supplementary Figure 1). Annotation of these variants with SpliceAI generally highlighted variants at positions with high MAPS scores (Supplementary Figure 2).

298 212 participants with a near-splice DNM had outcome data in the form of "exit questionnaires" from 299 their referring Genomic Medicine Centre. In 84/111 (76%) of solved cases, the diagnostic variant 300 matched our near-splice finding (Figure 2). This result gives us confidence in our approach to candidate 301 variant identification. Nevertheless, a significant proportion of participants with completed exit 302 questionnaires had unsolved cases (101/212, 48%). These included nine with a DNM in the CSS of a 303 known rare disease gene, one with a donor 0 variant, and four with donor +5 variants, which have previously been estimated to have a 90% positive predictive value in rare disease diagnosis⁸ (Figure 304 305 2).

For each participant and DNM, we manually reviewed the similarity between the HPO terms recorded at recruitment and the phenotype expected for a loss-of-function variant in that gene. Excluding any participants whose case was already solved through 100KGP, we identified 35 new likely diagnostic variants with at least a plausible phenotype match (Supplementary Table 2). In each instance, we

14

310 placed a clinical collaboration request with Genomics England to recruit the participant to the Splicing

and Disease Study for functional characterisation of the variant.

312 New diagnoses among the cohort

313 Whole blood RNA samples were obtained for five participants with near splice DNMs. RT-PCR was 314 used to characterise the splicing impact of each variant (Supplementary Figure 3). Abnormal splicing 315 events (all exon skipping) were detected in four participants (participants 74 (ARID1A, A-3), 249 (USP7, 316 D+5), 259 (TLK2, D+5), 261 (KAT6B, D+5)). In the remaining participant (participant 32 (PPP1R12A, A-21)), no disruption to splicing was observed (Table 1, Supplementary Figure 3). For two additional 317 318 participants where the candidate variant fell in a canonical splice site (participants 83 (TAOK1, A-2) & 319 94 (PHIP, A-2)), a new diagnosis was reached without the need for functional work based on ACMG 320 criteria with a PVS1 classification for these variants (Table 1, Supplementary Figure 3). 321 In summary, we demonstrate a functional splicing defect in four out of five participants recruited to

322 our study, and we have identified a new molecular diagnosis for six individuals to date.

323 Discussion

324 We examined WGS data from 38,688 individuals in the Rare Disease arm of the 100KGP to evaluate 325 the contribution of splicing variants to rare genetic diseases. Using a population-based metric of 326 constraint, MAPS, we showed that certain near-splice and (for the first time) branchpoint positions 327 are under strong purifying selection. We identified 258 *de novo* near-splice and branchpoint variants 328 in known disease genes in these families. We identified 35 likely diagnostic variants which had 329 previously been missed through the 100KGP, and we have confirmed a new molecular diagnosis for 330 six participants to date. Overall, we demonstrate the clinical value of examining both canonical and 331 non-canonical splicing variants in unsolved rare diseases.

332 Non-canonical splicing positions harbour deleterious splicing variants

We used three orthogonal approaches to estimate the deleteriousness of near-splice and branchpoint 333 variants: between-species conservation, within-species constraint, and splicing pathogenicity 334 335 prediction. The PhyloP, MAPS, and SpliceAI scores at splicing positions consistently highlight those 336 non-canonical splicing positions (especially D0 and D+5) which are likely to harbour damaging variants. 337 Indeed, three out of three D+5 variants in which we performed RNA studies caused exon skipping. 338 Importantly, although we use a cohort of unaffected parents as a proxy for a normal population, the 339 MAPS data we present is highly concordant with the strong signals of negative selection at which have 340 been previously described in the ExAC and DDD datasets⁸.

Extending this analysis to splicing branchpoints, we find strong signals of negative selection at a subset of branchpoint positions. These results are consistent with other measures of constraint previously described at bovine and human branchpoints³⁵. We also identified candidate diagnostic variants at these positions, and we are awaiting RNA samples to functionally characterise these variants. The disruption of splicing branchpoints may therefore make an important contribution to rare disease^{10,11}, and a systematic analysis of *de novo* variation at branchpoints is an exciting future research opportunity.

348 The ACMG variant interpretation guidelines give special status to CSS variants as "very strong" 349 diagnostic candidates in disorders where LoF is a known disease mechanism⁶. This remains the case 350 in more detailed guidance for the interpretation of LoF variants which has recently been introduced³⁶. 351 However, the deleteriousness of splicing variants is not binary, but on a continuum, and can be 352 quantitively compared to other variant classes. Previous estimates suggest that 46% of non-canonical 353 near-splice DNMs in dominant rare disease genes may be pathogenic, rising to 71% for pyrimidine to 354 purine transversions in the polypyrimidine tract, and 90% for D+5 variants⁸. The deleteriousness of 355 individual variants is contingent on many factors, such as local sequence context, the alternate 356 nucleotide, exon frame, exon length, and intron length⁹. For this reason, the systematic classification

16

of near-splice variants remains challenging, and clinical interpretation of these variants is still
 dependent on expert phenotype matching and functional validation of candidate variants.

359 The functional characterisation of splicing variants can be challenging and requires adequate amounts 360 of good quality RNA. Our study is limited by the use of blood as a proxy for the most clinically relevant 361 tissue, although we affirm the utility of blood RNA analysis by identifying splicing defects in four out 362 of five samples tested. Whereas RT-PCR is a bespoke and low-throughput approach, going forward, 363 RNA-sequencing (RNA-seq) offers an unbiased and high-throughput alternative to simultaneously 364 detect and functionally characterise splicing variants. A whole-transcriptome RNA-seq pilot study has 365 recently been proposed for 100KGP, and use of RNA-seq in routine clinical practice could offer a much-366 needed means to systematically and objectively interpret splicing variants³⁷.

367 New rare disease diagnoses

We identified 258 *de novo* SNVs overlapping near-splice or branchpoint regions of known monoallelic "loss of function" rare disease genes in 255 individuals. Of these, at least 84 were already considered to be diagnostic through 100KGP, and we identified an additional 35 variants which are likely to be diagnostic given the available molecular, phenotypic, and *in silico* data. We confirmed a new molecular diagnosis for six participants, including four participants for whom RNA studies were performed.

Surprisingly, several strong diagnostic candidates were apparently overlooked in the standard variant
interpretation pipeline, including at least nine CSS variants and four D+5 variants, all in known rare
disease genes. Of ten *de novo* D+5 variants, none were previously labelled as pathogenic, despite their
high prior probability of being diagnostic in this context⁸.

Clearly, many new diagnoses remain to be found. A recent analysis of 100KGP data in the context of craniosynostosis found that expert-led review more than doubled diagnostic yields compared to the standard pipeline³. An important factor is that the "virtual panels" applied to variant calls are outdated and do not include recently discovered disease genes. Our phenotype-matching work suggests that

381 the clinical impact of near-splice variants has been under-ascertained in this cohort, and we are 382 continuing to recruit participants for functional assessment of these variants.

383 One obstacle to increasing the number of researcher-identified diagnoses in this context is the 384 difficulty of recontacting de-identified participants and clinicians through secure research 385 environments. The confidentiality of all participants in research is rightly a priority, and new pathways 386 must be developed to streamline the clinical-research interface in medical genomics.

387 Conclusion

In conclusion, the disruption of splicing is an important cause of rare disease among 100KGP participants, but the contribution of non-canonical variants is still under-recognised. Splicing branchpoints are another non-canonical and non-coding source of damaging splicing variants which are amenable to systematic analysis in WGS data. The improved interpretation of splicing variants is an area of great promise to genomic medicine and, above all, to individuals with rare diseases and their families.

394 Supplemental data

395 Supplementary data include three figures and two tables.

396 Declaration of interests

397 The authors declare no competing interests.

398 Acknowledgements

The authors thank all participants and families involved in this research. We thank all clinicians and contributors who helped to assess potential splicing diagnoses, including: Ellen Thomas, Jessica Radley, Rebecca Igbokwe, Suresh Vijay, Deirdre Cilliers, Evan Reid, Mick Parker, David Hunt, Rachel Keen, Ed Blair, Helen Firth, Peggy O'Driscoll, Chiara Marini Bettol, Monish Suri, John Barton, Angela

Barnicoat, Sahar Mansour, Melody Redman, Kate Barr, Debbie Fuller, Meena Balasubramanian, Julia
Rankin, Sian Ellard, Olga Tsoulaki, and Emma Kivuva.

405 The Baralle lab is supported by NIHR Research Professorship awarded to D.B. (RP-2016-07-011). 406 Functional work was additionally supported by a Wessex Medical Research Innovation Grant awarded 407 to J.L. NW is currently supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust 408 and the Royal Society (Grant Number 220134/Z/20/Z) and funding from the Rosetrees Trust. AB was 409 supported by funding from Health Education England. We acknowledge the NIHR Clinical Research 410 Network (CRN) in recruiting participants and the Musketeers Memorandum, as well as support from 411 the NIHR UK Rare Genetic Disease Consortium. We thank Patrick J. Short for providing a curated set 412 of de novo variants used in earlier iterations of these analyses. This research was made possible through access to the data and findings generated by the 100,000 413

Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100,000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100,000 Genomes Project uses data provided by participants and collected by the National Health Service as part of their care and support.

420 Data and code availability

421 All code is available online at <u>https://github.com/alexblakes/100KGP_splicing</u>.

422 The data used in this study are available to registered users within a protected research environment

423 at https://www.genomicsengland.co.uk/about-gecip/for-gecip-members/data-and-data-access/.

424 References

- 425 1. International Rare Diseases Research Consortium. *Policies and guidelines*. (2013).
- Wright, C. F., FitzPatrick, D. R. & Firth, H. V. Paediatric genomics: Diagnosing rare disease in
 children. *Nat. Rev. Genet.* 19, 253–268 (2018).
- Hyder, Z. *et al.* Evaluating the performance of a clinical genome sequencing program for
 diagnosis of rare genetic disease , seen through the lens of craniosynostosis. (2021).
 doi:10.1038/s41436-021-01297-5
- 431 4. Sanders, S. J., Schwartz, G. B. & Farh, K. K. H. Clinical impact of splicing in neurodevelopmental
 432 disorders. *Genome Med.* 12, 1–5 (2020).
- 433 5. Wai, H., Douglas, A. G. L. & Baralle, D. RNA splicing analysis in genomic medicine. *Int. J.*434 *Biochem. Cell Biol.* 108, 61–71 (2019).
- 435 6. Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a joint
 436 consensus recommendation of the American College of Medical Genetics and Genomics and

437 the Association for Molecular Pathology. *Genet. Med.* **17**, 405–423 (2015).

- 438 7. Rivas, M. A. *et al.* Effect of predicted protein-truncating genetic variants on the human
 439 transcriptome. *Science (80-.).* 348, 666–669 (2015).
- 440 8. Lord, J. *et al.* Pathogenicity and selective constraint on variation near splice sites. *Genome Res.*441 **29**, 159–170 (2019).
- 442 9. Zhang, S. *et al.* Base-specific mutational intolerance near splice sites clarifies the role of
 443 nonessential splice nucleotides. *Genome Res.* 28, 968–974 (2018).
- Kapoor, R. R. *et al.* Persistent hyperinsulinemic hypoglycemia and maturity-onset diabetes of
 the young due to heterozygous HNF4A mutations. *Diabetes* 57, 1659–63 (2008).
- 446 11. Fadaie, Z. et al. BBS1 branchpoint variant is associated with non-syndromic retinitis

- 447 pigmentosa. J. Med. Genet. (2021). doi:10.1136/jmedgenet-2020-107626
- Lek, M. *et al.* Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 536, 285–
 291 (2016).
- 450 13. Whiffin, N. *et al.* Characterising the loss-of-function impact of 5' untranslated region variants
- 451 in 15,708 individuals. *Nat. Commun.* **11**, 1–12 (2020).
- 452 14. Rowlands, C. F. & Baralle, D. Machine Learning Approaches for the Prioritization of Genomic
 453 Variants Impacting Pre-mRNA Splicing. (2019).
- 454 15. Jaganathan, K. *et al.* Predicting Splicing from Primary Sequence with Deep Learning. *Cell* **176**,
 455 535-548.e24 (2019).
- 456 16. Rowlands, C. *et al.* Comparison of in silico strategies to prioritize rare genomic variants
 457 impacting RNA splicing for the diagnosis of genomic disorders. *Sci. Rep.* **11**, 20607 (2021).
- 458 17. Smedley, D. *et al.* 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care —
 459 Preliminary Report. *N. Engl. J. Med.* 385, 1868–1880 (2021).
- 460 18. Genomics England. *The National Genomics Research Library*. (2020).
 461 doi:https://doi.org/10.6084/m9.figshare.4530893.v7
- 462 19. Frankish, A. *et al.* GENCODE reference annotation for the human and mouse genomes. *Nucleic*463 *Acids Res.* 47, D766–D773 (2019).
- Pollard, K. S., Hubisz, M. J., Rosenbloom, K. R. & Siepel, A. Detection of nonneutral substitution
 rates on mammalian phylogenies. *Genome Res.* 20, 110–121 (2010).
- 466 21. Ryan, D. P. pyBigWig. (2015). Available at: https://github.com/deeptools/pyBigWig.
- 467 22. Kent, W. J. et al. The Human Genome Browser at UCSC. Genome Res. 12, 996–1006 (2002).
- 468 23. Kent, W. J., Zweig, A. S., Barber, G., Hinrichs, A. S. & Karolchik, D. BigWig and BigBed: Enabling
- 469 browsing of large distributed datasets. *Bioinformatics* **26**, 2204–2207 (2010).

21

- 470 24. Danecek, P. et al. Twelve years of SAMtools and BCFtools. Gigascience 10, (2021).
- 471 25. Quinlan, A. R. & Hall, I. M. BEDTools: A flexible suite of utilities for comparing genomic features.
- 472 Bioinformatics **26**, 841–842 (2010).
- 473 26. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 1–14 (2016).
- 474 27. Short, P. J. *et al.* De novo mutations in regulatory elements in neurodevelopmental disorders.
- 475 *Nature* **555**, 611–616 (2018).
- 476 28. Samocha, K. E. *et al.* A framework for the interpretation of de novo mutation in human disease.
 477 *Nat. Genet.* 46, 944–950 (2014).
- Paggi, J. M. & Bejerano, G. A sequence-based, deep learning model accurately predicts RNA
 splicing branchpoints. *Rna* 24, 1647–1653 (2018).
- 480 30. UCSC. Lift Genome Annotations. Available at: https://genome.ucsc.edu/cgi-bin/hgLiftOver.
 481 (Accessed: 25th August 2020)
- 482 31. Genomics England de novo variant research dataset. Available at: https://research 483 help.genomicsengland.co.uk/display/GERE/De+novo+variant+research+dataset. (Accessed:
- 484 23rd November 2021)
- 485 32. Thormann, A. *et al.* Flexible and scalable diagnostic filtering of genomic variants using G2P with
 486 Ensembl VEP. *Nat. Commun.* 10, 1–10 (2019).
- 487 33. Genomics England. Rare Disease Results Guide. (2020).
- 488 34. Tomita, M., Shimizu, N. & Brutlag, D. L. Introns and reading frames: Correlation between
 489 splicing sites and their codon positions. *Mol. Biol. Evol.* 13, 1219–1223 (1996).
- 490 35. Kadri, N. K., Mapel, X. M. & Pausch, H. The intronic branch point sequence is under strong
 491 evolutionary constraint in the bovine and human genome. *Commun. Biol.* 4, 1206 (2021).
- 492 36. Abou Tayoun, A. N. et al. Recommendations for interpreting the loss of function PVS1


- 493 ACMG/AMP variant criterion. *Hum. Mutat.* **39**, 1517–1524 (2018).
- 494 37. Cummings, B. B. et al. Improving genetic diagnosis in Mendelian disease with transcriptome
- 495 sequencing. *Sci. Transl. Med.* **9**, (2017).

496

497 Figures


498 Figure 1

499 Conservation, predicted splice disruption, and constraint at near-splice and branchpoint positions across 207,548 CDS features in protein coding genes. A: Position-weight matrices and schematic 500 501 indicating position of conserved splicing motifs relative to exon / intron boundaries. B: Mean phyloP 502 100-way scores at splicing positions. Error bars indicate 95% confidence intervals. C: SpliceAI scores 503 for all possible near splice SNVs. Scores represent the mean probability that any variant at this position 504 disrupts splicing, as predicted by SpliceAI (see Methods). Error bars represent the 95% confidence 505 interval. D: Mutability-adjusted proportion of singletons (MAPS) for both coding and near-splice SNVs. 506 Error bars indicate 95% confidence intervals. Positions with a significantly higher MAPS than 507 synonymous variants are indicated with open circles (see Methods). For branchpoint positions, dark 508 blue points represent all putative branchpoints, whereas light blue points represent branchpoints with 509 a LaBranchoR score >0.85



510 Figure 2

Participant outcomes for rare disease probands with *de novo* splicing variants in known monoallelic loss-of-function rare disease genes. Each point represents a DNM in a rare disease proband. Points are coloured by the clinical outcome for that individual. Crosses indicate variants which were identified as likely new diagnoses in this study. Where a variant overlaps both a branchpoint and a splice acceptor position, only the splice acceptor annotation is given.



516 Tables

517 Table 1

518 Diagnostic outcomes for seven individuals after clinical and functional characterisation of the splicing 519 variant. Five individuals underwent RNA studies, of which four received a new diagnosis. In two 520 additional individuals, a diagnosis was reached without the need for RNA studies. In total, a new 521 diagnosis was confirmed for six individuals. Note that the given HPO terms are "abstracted" (see 522 Methods) to protect confidentiality. * In participants 83 and 94, a new diagnosis was reached without 523 the need for functional evaluation. ** This exit questionnaire outcome was updated after the 524 participant was identified by this study.

ID Chrom	Dec De	5 A 14	Decion	Site Symbol	ENST [o Tior Movti	er Exit questionnaire	HPO terms (abstracted)	Splicing impact	Outcome
74 chr1	26767787 C			-3 ARID1A	ENST00000324856	0.71	0.65 DS_AL	3	3 No data	Aplasia/Hypoplasia of the mandible, Advanced eruption of teeth, Abnormal pulmonary valve morphology, Abnormality of calvarial morphology, Abnormality of cardiovascular system morphology, Oral cleft	Exon skipping	New diagnosis
261 chr10	74989117 G	Α		5 KAT6B	ENST0000287239	0.98	0.98 DS_DL	3	3 Case not solved	Hypothyroidism	Exon skipping	New diagnosis
259 chr17	62596679 G	A	donor	5 TLK2	ENST00000326270	0.97	0.96 DS_DL	3	3 Case not solved	Abnormality of globe location, Abnormal facial shape, Facial asymmetry, Abnormal heart sound, Cutaneous syndactyly, Abnormal ear morphology, Neurodevelopmental delay, Short stature, Abnormal digit morphology, Decreased body weight, Intrauterine growth retardation, Abnormality of higher mental function, Motor delay, Language impairment, Gait disturbance, Abnormal location of ears	Exon skipping	New diagnosis
249 chr16	8905182 C	A	donor	5 USP7	ENST00000344836	0.932	0.8 DS_DL	3	3 Case not solved	Motor delay, Abnormal size of the palpebral fissure, Abnormal hair quantity, Abnormality of globe location, Facial hypertrichosis, Neurological speech impairment, Abnormality of higher mental function, Abnormal metatarsal morphology	Exon skipping	New diagnosis
94 chr6	79002126 T	G	acceptor	-2 PHIP	ENST00000275034	1	1 DS_AL	3	2 Case not solved	Abnormality of higher mental function, Motor delay, Neurodevelopmental delay, Macrotia, Language impairment, Finger clinodactyly, Abnormal muscle tone, Facial hypertrichosis	N/A	New diagnosis*
83 chr17	29491782 A	G	acceptor	-2 TAOK1	ENST00000261716	0.992	0.99 DS_AL	3	3 Case solved, same variant**	Renal agenesis, Hemangioma, Abnormality of joint mobility, Hypotonia, Increased head circumference, Neurodevelopmental delay	N/A	New diagnosis*
32 chr12	79808598 T	A	acceptor	-21 PPP1R12A	ENST00000450142	0	0 DS_AG	N/A	3 Case not solved	Increased head circumference, Abnormal thorax morphology, Bowing of the legs, Growth delay, Limb undergrowth, Abnormality of joint mobility, Short digit, Neurodevelopmental abnormality, Abnormality of movement	Normal splicing	Unsolved

526 Supplementary Figures

527 Supplementary Figure 1

- 528 Tiering data for splicing DNMs in known monoallelic loss-of-function rare disease genes. Each point 529 represents a DNM in a rare disease proband. Points are coloured by the "tier" of that variant in the
- 525 represents a billion in a fare disease proband. Fornts are coloured by the filer of that varian
- 530 GEL annotation pipeline (see Methods).

531 Supplementary Figure 2

- 532 SpliceAI scores of splicing DNMs in known monoallelic loss-of-function rare disease genes. Each point
- represents a DNM in a rare disease proband. Points are coloured by SpliceAI score; grey points indicate
- that no SpliceAI annotation is available.

535 Supplementary Figure 3

Functional outcomes for participant samples which were characterised by RT-PCR. Each page illustrates the following: a schematic of variant position relative to the exon/intron junction, a schematic of the splicing consequence of each variant, gel electrophoresis of amplified RT-PCR products for participant and control samples, Sanger sequencing trace for proband-specific bands.

540 Supplementary tables

541 Supplementary Table 1

542 Molecular details and clinical outcome data for the 258 prioritised DNMs. Rows in bold indicate those

543 variants identified as likely to be diagnostic, which are given in Supplementary Table 2 ("Main" DNM

set). * This exit questionnaire outcome was updated after the participant was identified by this study.

545 Supplementary Table 2

546 Molecular details and phenotypic data for 35 likely diagnostic variants in "unsolved" probands. Each variant was judged to be at least a plausible diagnostic fit given the phenotype information available. 547 Note that the given HPO terms are "abstracted" (see Methods) to prevent participant re-identification. 548 549 Also note that of the 35 diagnostic candidates, 8 were identified in a preliminary set of DNMs used for 550 exploratory analysis at the inception of this project, and are not among the 258 prioritised DNMs (Supplementary Table 1) described in more detail above (see Methods). Participants in bold are those 551 shown in Table 1. * This exit questionnaire outcome was updated after the participant was identified 552 553 by this study.